Short Reads

Huawei v ZTE: ECJ rules on injunction possibility of SEP owner against alleged infringer after a FRAND licensing proposal – abuse of dominant position

Huawei v ZTE: ECJ rules on injunction possibility of SEP owner against alleged infringer after a FRAND licensing proposal – abuse of dominant position

Huawei v ZTE: ECJ rules on injunction possibility of SEP owner against alleged infringer after a FRAND licensing proposal – abuse of dominant position

12.08.2015 BE law

The European Court of Justice (“ECJ”) handed down its decision on July 16, 2015 in the case Huawei v. ZTE (C-170/13). It clarified the possibility for owners of a standard-essential patent (“SEP”) to seek an injunction against alleged infringers.

Also available in French and Dutch. 

The case concerns a request for preliminary ruling by the Dusseldorf Regional Court, who requests the ECJ to answer to the question whether Huawei is abusing its dominant position as an SEP owner by seeking an injunction against ZTE for the use of Huawei’s LTE patented technology without paying royalties to the latter. 

According to the ECJ, an SEP owner who seeks an injunction as a result of the alleged unauthorized use of its patented technology by a third party does not abuse its dominant position, in the sense of Article 102 of the Treaty on the Functioning of the EU (“TFEU”), if:

  1. The SEP owner has  notified the third party about the alleged infringement;
  2. The SEP owner has presented a Fair, Reasonable, and Non Discriminatory (“FRAND”) licensing proposal to said third party;
  3. After having received the notice and proposal (mentioned in 1 and 2 above), the alleged infringer continues to use the SEP owner’s patented technology without responding to the SEP owner that it is willing to enter into FRAND licensing negotiations.

The ECJ further clarified that an alleged infringer that has not accepted a licensing offer can only assert that the SEP owner is abusing its dominant position if the alleged infringer has actually responded to the FRAND licensing offer with a written counter-offer.

Although this decision gives some clarification on the matter, several questions remain unanswered. For example, the ECJ did not clarify what can be considered as a FRAND licensing offer. Further, if the parties have submitted a FRAND offer and counter-offer, but they cannot come to an agreement, litigation concerning unauthorized use of the patent will still be inevitable.


Related news

02.09.2019 BE law
Philippe Campolini rejoint l’éminente pratique IP de Stibbe en qualité d’associé

Inside Stibbe - Bruxelles, 2 septembre 2019 – Le cabinet de Stibbe Bruxelles est ravi d’accueillir Philippe Campolini, avocat spécialisé en droit de la propriété intellectuelle et des sciences de la vie, en tant que nouvel associé. Son arrivée vient non seulement renforcer la pratique de référence du cabinet en la matière, mais également répondre à l’évolution des besoins du marché. Philippe rejoint le cabinet Stibbe le 2 septembre 2019. Il travaillera en étroite collaboration avec Ignace Vernimme, associé spécialisé en droit de la propriété intellectuelle.

Read more

02.09.2019 BE law
Philippe Campolini joins Stibbe’s leading IP practice as partner

Inside Stibbe - Brussels, 2 September 2019 – Stibbe is delighted to welcome IP lawyer and life sciences specialist Philippe Campolini as new partner in its Brussels office. Stibbe’s hiring of Philippe reinforces the firm’s leading intellectual property practice and responds to developing market needs. Philippe joins Stibbe on 2 September 2019 and will team up with IP law partner Ignace Vernimme.

Read more

21.03.2019 EU law
Ignace Vernimme, Floris ten Have and Manuel Campolini are speakers during the Legal Affairs Conference.

Speaking slot - Ignace Vernimme, IP Partner at Stibbe Brussels, moderates a roundtable discussion on 'second medical use patents'. Manuel Campolini, of-counsel at Stibbe Brussels, co-moderates this session. Floris ten Have, Competition and Regulation Partner at Stibbe Amsterdam, chairs a session on opportunities and challenges for biosimilar medicine developers.

Read more

02.09.2019 BE law
Stibbe verwelkomt Philippe Campolini als partner in praktijk intellectuele eigendom

Inside Stibbe - Brussel, 2 september 2019 – Stibbe is verheugd om Philippe Campolini als nieuwe vennoot in zijn Brussels kantoor te verwelkomen. Philippe is gespecialiseerd in het intellectueel eigendomsrecht en de life sciences sector. Zijn komst versterkt Stibbe’s toonaangevende IP-praktijk en beantwoordt aan nieuwe marktbehoeften in dit rechtsdomein. Philippe vervoegt Stibbe op 2 september 2019 en zal nauw samenwerken met IP-vennoot Ignace Vernimme.

Read more

21.03.2019 NL law
15 aspects of Brexit you did not know

Short Reads - A Brexit without a deal, or with a deal that does not cover all relevant aspects, is still a potential scenario. We have highlighted a number of unexpected legal consequences of Brexit in such a no deal or incomplete deal scenario.

Read more

Our website uses functional cookies for the functioning of the website and analytic cookies that enable us to generate aggregated visitor data. We also use other cookies, such as third party tracking cookies - please indicate whether you agree to the use of these other cookies:

Privacy – en cookieverklaring